舌下神经刺激与心血管疾病发病率的关系
这项回顾性队列研究利用Merative MarketScan商业数据库,纳入3786例接受舌下神经刺激(HGNS)的成人及3395例符合HGNS适应症但未植入的对照,按倾向评分匹配。结果显示HGNS与2年内高血压及心血管事件风险升高相关,但2年后糖尿病、高血压及心血管事件风险均降低,提示HGNS可能具有长期心血管获益,但需进一步研究验证。
要点
- HGNS术后2年内高血压诊断风险升高(HR 1.70),但2年后风险降低(HR 0.49)。
- 基线有糖尿病或高血压者,HGNS术后2年内小/大心血管事件风险升高,2年后风险开始下降。
- 无基线心血管病者,HGNS术后2年后糖尿病风险显著降低(HR 0.19)。
核心结论
- HGNS与心血管结局的关联随时间变化,长期可能降低糖尿病、高血压及心血管事件风险,但2年内风险升高。
- 研究结果支持进一步验证HGNS对心血管疾病的长期保护作用。
研究设计与样本
- 回顾性队列研究,使用Merative MarketScan商业数据库。
- 纳入2015至2024年间接受HGNS的成人3786例,匹配符合HGNS适应症但未植入的对照3395例。
- 采用倾向评分匹配,匹配变量包括基线协变量、确诊OSA年数及索引访视年份。
主要发现
- 无基线心血管病者中,HGNS与2年内糖尿病诊断无显著关联(HR 1.06;95% CI 0.61-1.85),2年后风险降低(HR 0.19;95% CI 0.09-0.38)。
- 无基线心血管病者中,HGNS与2年内高血压诊断风险升高相关(HR 1.70;95% CI 1.26-2.28),2年后风险降低(HR 0.49;95% CI 0.33-0.73)。
- 基线有糖尿病或高血压者中,HGNS与2年内小心血管事件风险升高相关(HR 1.44;95% CI 1.06-1.95),2年后无显著关联(HR 0.60;95% CI 0.35-1.04),但风险开始下降(HR 0.42;95% CI 0.22-0.79)。
- 基线有糖尿病或高血压者中,HGNS与2年内大心血管事件风险升高相关(HR 1.62;95% CI 1.06-2.48),2年后无显著关联(HR 0.65;95% CI 0.31-1.36),但风险开始下降(HR 0.40;95% CI 0.17-0.93)。
临床怎么用
- 临床决策时应告知患者HGNS术后短期内可能增加高血压及心血管事件诊断风险,但长期可能降低糖尿病、高血压及心血管事件风险。
- 对接受HGNS的OSA患者,术后2年内需加强血压和心血管事件监测,尤其是基线已有糖尿病或高血压者。
局限性
- OSA和心血管疾病的严重程度未纳入匹配。
- 回顾性设计可能残留混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: As hypoglossal nerve stimulation (HGNS) grows as an obstructive sleep apnea (OSA) treatment option, health risk reduction data are needed. OBJECTIVE: To determine whether HGNS is associated with lower incidence of cardiovascular disease (CVD). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted using the Merative MarketScan Commercial Database. Adults undergoing HGNS between 2015 and 2024 were matched to controls meeting HGNS candidacy criteria (ie, diagnosed with OSA, nonadherent to positive airway pressure therapy) who did not undergo implantation. INTERVENTIONS: Patients undergoing HGNS were matched on propensity scores estimated by baseline covariates, years with confirmed OSA, and index visit year. OSA and CVD severity were not available for matching. MAIN OUTCOME AND MEASURES: For patients without baseline CVD, outcomes were time from index visit to diagnosis of diabetes or hypertension. For patients with baseline diabetes or hypertension, outcomes were time from index visit to diagnosis of a minor or major cardiovascular event. HGNS was modeled with a time-varying covariate because surgery was not expected to affect diagnoses until after 2 years. RESULTS: The population included 3786 patients who underwent HGNS (median [IQR] age, 53.0 [44.0-59.0] years; 2562 [67.7%] male) and 3395 controls. Among patients without baseline CVD, HGNS (1) was not associated with diabetes diagnosis within 2 years (HR, 1.06; 95% CI, 0.61-1.85) but was associated with lower hazard after 2 years (HR, 0.19; 95% CI, 0.09-0.38), and (2) was associated with higher hazard of hypertension diagnosis within 2 years (HR, 1.70; 95% CI, 1.26-2.28) but lower hazard after 2 years (HR, 0.49; 95% CI, 0.33-0.73). Among patients with baseline diabetes or hypertension, HGNS was associated with higher hazard of a minor (HR, 1.44; 95% CI, 1.06-1.95) or major (HR, 1.62; 95% CI, 1.06-2.48) cardiovascular event diagnosis within 2 years but not associated after 2 years (minor: HR, 0.60; 95% CI, 0.35-1.04; major: HR, 0.65; 95% CI, 0.31-1.36), though the hazards after 2 years began decreasing (minor: HR, 0.42; 95% CI, 0.22-0.79; major: HR, 0.40; 95% CI, 0.17-0.93). CONCLUSIONS AND RELEVANCE: The findings of this cohort study indicate variable but potential longer-term cardiovascular benefits of HGNS and motivate research to verify these associations, explore subgroup differences, and investigate mechanisms underlying potential changes in cardiovascular outcomes after HGNS.
引用
- Kondamuri N, Hyman MJ, Cai Y, et al. Hypoglossal Nerve Stimulation and the Incidence of Cardiovascular Disease. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42461651. doi:10.1001/jamaoto.2026.1777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。